Novo Nordisk A/S has been identified as one of the most undervalued foreign stocks to buy following a first-quarter profit beat [1].
The assessment comes as the Danish pharmaceutical company leverages the massive growth of its GLP-1 product line, specifically Wegovy, to expand its global market share. This financial momentum suggests that the company's current stock price may not fully reflect its long-term growth prospects [2].
On May 6, 2026, the company released its first-quarter earnings report, which showed that sales jumped 32% on a constant-currency basis [3]. This performance allowed Novo Nordisk to top profit forecasts for the period [1]. Following the announcement, the company's stock, which is listed on the NYSE under the ticker NVO, rose about seven percent in early trading [4].
Despite the strong start to the year, the company provided a complex updated outlook. Novo Nordisk adjusted its full-year guidance to expect sales and profit to contract between four percent and 12% [3]. This adjustment stands in contrast to the immediate growth seen in the first quarter, a move that analysts are monitoring closely as the company scales its operations.
Headquartered in Denmark, Novo Nordisk continues to dominate the weight-loss drug market. The surge in demand for GLP-1 medications has positioned the company as a primary driver of pharmaceutical growth in the foreign equity sector [2]. Analysts said that the combination of an upgraded outlook and the scale of Wegovy sales makes the stock an attractive option for investors [2].
“First-quarter sales jumped 32% on a constant-currency basis”
The discrepancy between Novo Nordisk's immediate quarterly growth and its projected annual contraction suggests a period of volatile scaling. While the 32% sales jump proves the massive demand for GLP-1 drugs, the cautious full-year guidance may reflect supply chain constraints or pricing pressures. For investors, the 'undervalued' label indicates a belief that the long-term utility of Wegovy outweighs these short-term fiscal adjustments.
